13.7 C
Wednesday, May 29, 2024

Novo Nordisk inventory worth drops as diabetes and weight-loss medicine Ozempic and Saxenda investigated | World Information

Must read

- Advertisement -

Two medicine used as diabetes and weight-loss therapies are being investigated after some sufferers reported having suicidal ideas.

Each Ozempic and Saxenda are being investigated by the European Medicines Company (EMA), after Iceland’s well being regulator flagged two {cases} of Ozempic sufferers having suicidal ideas and one on Saxenda desirous about self-harm.

Ozempic, which accommodates the lively ingredient semaglutide, was designed as a diabetes remedy however has gained popularity as a “miracle” weight-loss aid.

It’s produced by Novo Nordisk, the Danish drugmaker. Shares within the agency fell by 1% on Monday following information of the investigation, Reuters reported.

Novo’s earlier and fewer efficient weight-loss drug, Saxenda, can also be an injection that suppresses urge for food.

- Advertisement -

It accommodates liraglutide and within the UK is accessible on prescription as part of a weight administration plan.

Novo Nordisk mentioned affected person security was its prime precedence and it handled all reviews about adversarial occasions very severely.

Its security monitoring had up to now discovered no “causal affiliation” between the self-harming ideas and the medicine, it mentioned in a press release.

Suicidal ideas should not listed as a facet impact within the EU product info for both drug.

However within the US, prescribing directions for Wegovy – which additionally accommodates semaglutide – say sufferers needs to be monitored for suicidal ideas or behaviour.

The warning is there due to dangers related to different weight administration medicine, relatively than as a result of drug trials steered an elevated threat of suicidal behaviour, the US Meals and Drug Administration (FDA) mentioned.

Please use Chrome browser for a extra accessible video participant

Scarcity of ‘miracle’ weight-loss drug

Learn extra:
Next wave of weight-loss jabs could be coming – without the side effects
Obesity patients feel like ‘second-class citizens’ as Ozempic demand soars

There have been no less than 60 reviews of suicidal ideas in sufferers on semaglutide since 2018, in response to the FDA’s Hostile Occasion Reporting System (FAERS).

At the very least 70 reviews of suicidal considering in customers of liraglutide have been made to the FAERS since 2010.

Data in these reviews has not been verified and a report will not be proof of causation, the FDA mentioned.

The EMA mentioned it could contemplate whether or not its overview needs to be prolonged to different medicines that regulate urge for food by mimicking a intestine hormone, generally known as GLP-1 receptor agonists.

Source link

More articles

- Advertisement -

Latest article